Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity: a Single Blind, Non-inferiority, Randomised Clinical Trial

NCT04222920 is registered in ClinicalTrials.gov with Reade Rheumatology Research Institute as lead sponsor.

NCT NCT04222920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04222920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity: a Single Blind, Non-inferiority, Randomised Clinical Trial
Lead sponsor
Reade Rheumatology Research Institute
Phase
Phase 4
Overall status
Completed
Start date
March 1, 2020
Completion date
September 11, 2023
Enrollment
78 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis